anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Women who will be referred to the maternity ward of both hospitals for a checkup and have the inclusion criteria will be offered admission for at least 24 hours to have complete rest aiming to increase the placental blood circulation of the uterus, which by itself can improve the amniotic fluid level. Patients will be randomly allocated into two groups according to a trial sequence determined via a computer generated random table. The trial sequence is hidden into opaque sequenced envelopes as each envelope contains an assignment for a single patient. Patients in first group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour in addition to sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily and the same fluid regimen will be used in control group but without sildenafil citrate treatment. During hospital course maternal monitoring will be done using maternal vital signs for early detection of any manifestations of fluid overload while fetal monitoring will be done using non-stress test and all patients less than 34 completed weeks will receive dexamethasone in a total dose of 24mg to enhance fetal lung maturity in case expedited delivery is needed. Fasting will also be recommended during fluid therapy in case any emergency interference is required then all patients will resume their usual daily diet and fluid intake. All patients will then undergo sonography after 24 hours for reassessment of amniotic fluid index and those who will show an improvement of at least 20% will be discharged home and for those who still show no results the same regimen will be repeated. Discharged patients in first group will be asked to continue sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily plus a daily oral fluid intake of 2 liters while those in the control group will be asked only to have 2 liters daily oral fluid. Outpatient monitoring in both groups will depend on twice weekly non-stress test and once weekly amniotic fluid index and biophysical profile. Readmission and inpatient therapy using same protocol in each group will be indicated at any time if amniotic fluid index reduced to ≤ 5 cm. All patients also will be instructed to undergo periods of bed rest and, also they will be educated to count fetal kicks and to report immediately to the hospital if being unsatisfactory.

Patients in both groups will be monitored till they will go into spontaneous labor or till delivery will be indicated. The primary outcome measure will be the values of amniotic fluid index before and after therapy in each group and between both groups. The secondary outcome measures will be mode of delivery, gestational age at birth, fetal birth weight, and fetal and neonatal outcomes (Apgar scores, umbilical artery acid-base analysis at birth, and the need for transfer to the neonatal intensive care unit) which will be analyzed for the study and control groups.
Hyperuricemia (HUA) is a condition associated with a high concentration of uric acid (UA) in the bloodstream and can cause gout and chronic kidney disease. The gut microbiota of patients with gout and HUA is significantly altered compared to that of healthy people. This article focused on the complex interconnection between alterations in the gut microbiota and the development of this disorder. Some studies have suggested that changes in the composition, diversity, and activity of microbes play a key role in establishing and progressing HUA and gout pathogenesis. Therefore, we discussed how the gut microbiota contributes to HUA through purine metabolism, UA excretion, and intestinal inflammatory responses. We examined specific changes in the composition of the gut microbiota associated with gout and HUA, highlighting key bacterial taxa and the metabolic pathways involved. Additionally, we discussed the effect of conventional gout treatments on the gut microbiota composition, along with emerging therapeutic approaches that target the gut microbiome, such as the use of probiotics and prebiotics. We also provided insights into a study regarding the gut microbiota as a possible novel therapeutic intervention for gout treatment and dysbiosis-related diagnosis.
PURPOSE:To prepare fine particles industrially and advantageously under mild temperature conditions, by adding polyvinylpyrrolidone to an organic solvent system containing a biodegradable polymer and a physiologically active substance as a core material, and crystallizing polymer at a specific temperature. CONSTITUTION:Fine powder of a core material, e.g. physiologically active substance such as a carcinostatic agent, is dispersed or dissolved in a solution containing a biodegradable aliphatic polyester, e.g. poly-L-lactic acid, in a good solvent, e.g. methylene chloride, and polyvinylpyrrolidone is then added thereto. A liquid fat or oil, e.g. soybean oil, as a poor solvent is added to the resultant dispersion or solution. Fine particles are then deposited and hardened at -20- +50 deg.C, and the continuous phase is removed. The resultant fine particles are washed and dried to give the aimed fine particles. USE:Fine particles for prolonged release type drugs.
The research will be carried out in two stages. In Stage 1, the game will be developed; The developed game's effectiveness will be evaluated in the 2nd stage by testing it. The game's content will include healthy nutrition, exercise, foot care, insulin use, and hypoglycemia management. When the games are completed, the virtual coach will step in, and the participants will be given motivational feedback. The game developed will be evaluated by the patients in the second stage with a two-week pilot period. It will be updated according to the feedback received. The final version of the game will be passed forward to the implementation phase. Individuals who are willing to participate in the study coming to Prof. Dr. Cemil Tascioglu City Hospital Diabetes Polyclinic will be randomly assigned to the intervention and control groups. A total of 88 patients (44 controls - 44 experiments) are planned to be recruited. In the first interview with the individuals in the intervention group, Within the scope of the pretest, the "Personal Information Form," "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" will be used for evaluation. Outpatient appointment dates of the sixth week of the intervention program, "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" forms will be used with patients for the final evaluation within the scope of the posttest.

In the first meeting with the individuals in the control group, explanations about the research will be made. After their written consent is obtained at the first interview and within the scope of the pretest, the "Personal Information Form," "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" will be used for evaluation. At the end of the sixth week of the study, when they come in for their outpatient clinic appointments, as a part of the posttest, "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" forms will be used for the final evaluation.
Cyclosporine oral solution, USP MODIFIED has increased bioavailability compared to Sandimmune (cyclosporine oral solution, USP). The absolute bioavailability of cyclosporine administered as Sandimmune (cyclosporine oral solution, USP) is dependent on the patient population, estimated to be less than 10% in liver transplant patients and as great as 89% in some renal transplant patients. The absolute bioavailability of cyclosporine administered as cyclosporine oral solution, USP MODIFIED has not been determined in adults. In studies of renal transplant, rheumatoid arthritis and psoriasis patients, the mean cyclosporine AUC was approximately 20% to 50% greater and the peak blood cyclosporine concentration (Cmax) was approximately 40% to 106% greater following administration of cyclosporine oral solution, USP MODIFIED compared to following administration of Sandimmune (cyclosporine oral solution, USP). The dose normalized AUC in de novo liver transplant patients administered cyclosporine oral solution, USP MODIFIED 28 days after transplantation was 50% greater and Cmax was 90% greater than in those patients administered Sandimmune (cyclosporine oral solution, USP). AUC and Cmax are also increased (cyclosporine oral solution, USP MODIFIED relative to Sandimmune (cyclosporine oral solution, USP)) in heart transplant patients, but data are very limited. Although the AUC and Cmax values are higher on cyclosporine oral solution, USP MODIFIED relative to Sandimmune (cyclosporine oral solution, USP), the predose trough concentrations (dose-normalized) are similar for the two formulations.

Following oral administration of cyclosporine oral solution, USP MODIFIED, the time to peak blood cyclosporine concentrations (Tmax) ranged from 1.5 to 2.0 hours. The administration of food with cyclosporine oral solution, USP MODIFIED decreases the cyclosporine AUC and Cmax. A high fat meal (669 kcal, 45 grams fat) consumed within one-half hour before cyclosporine oral solution, USP MODIFIED administration decreased the AUC by 13% and Cmax by 33%. The effects of a low-fat meal (667 kcal, 15 grams fat) were similar.

The effect of T-tube diversion of bile on the absorption of cyclosporine from cyclosporine oral solution, USP MODIFIED was investigated in eleven de novo liver transplant patients. When the patients were administered cyclosporine oral solution, USP MODIFIED with and without T-tube diversion of bile, very little difference in absorption was observed, as measured by the change in maximal cyclosporine blood concentrations from pre-dose values with the T-tube closed relative to when it was open: 6.9 ± 41% (range 55% to 68%).
PURPOSE: To accurately measure neopterin, even in a fresh humor by adding an oxidizing agent to a reagent being used for treating a humor in an immuoassay of neopterin, employing a specific antibody for neopterin and a detection system. CONSTITUTION: An oxidizing agent is added to a reagent being used for treating a humor in an immuoassary of neopterin. Appropriate oxidizing agents include potassium or sodium hexacyanoferrate (III), ferrate (III)/chelate agent, peroxosulfate, peroxoborate, or nitropruside wherein the concentration of potassium hexacyanoferrate (III) is preferably 0.05-100mmol/l, and more preferably 0.5-50mol/l. The oxidizing agent has high ion intensity and used as an aqueous solution buffered in the range of pH5-10, preferably of pH7-8. The concentration is set in the range of 50-300mmol/l, preferably of 150-250mmol/l. More specifically incubation of reactive elements is performed entirely under the presence of an oxidizing agent.
A cross-sectional survey will be conducted among 200 volunteering women aged 18-45 years and having had prior sexual activity living in the target villages of Itilima and Maswa districts, North-western Tanzania. A single midday urine sample and two cervical-vaginal swabs (both self-collected and speculum-aided collected by a female healthcare worker) will be obtained from participating women and processed using urine filtration and polymerase chain reaction (PCR) for cervico-vaginal samples. A pre-tested structure questionnaire will be used to collect sociodemographic, clinical, and sampling acceptability information from participants. Prevalence of Female Genital Schistosomiasis (FGS) will be estimated based on positivity of at least one genital specimen. Quantitative data will be described using means/medians and standard deviation/interquartile range, as appropriate. Qualitative data will be described as numbers and percentages, and compared using Chi-squared or Fisher Exact test, as appropriate. Sensitivity of the two genital sampling methods will be compared using the composite reference constituted by positivity in at least one genital swab, and the performance of the two methods compared using Cohen's Kappa statistics, Fisher's Exact test and parametric/nonparametric test for comparison of PCR Ct values, as appropriate.
Sleep and circadian temperature disturbances occur with spaceflight and may, in part, result from the chronically elevated carbon dioxide (CO2) levels on the international space station. Impaired sleep may contribute to decreased glymphatic clearance and, when combined with the chronic headward fluid shift during actual spaceflight or the spaceflight analog head-down tilt bed rest (HDTBR), may contribute to the development of optic disc edema. We determined if strict HDTBR combined with mildly elevated CO2 levels influenced sleep and core temperature and was associated with the development of optic disc edema. Healthy participants (5 females) aged 25-50 yr, underwent 30 days of strict 6° HDTBR with ambient Pco2 = 4 mmHg. Measures of sleep, 24-h core temperature, overnight transcutaneous CO2, and Frisén grade edema were made pre-HDTBR, on HDTBR days 4, 17, 28, and post-HDTBR days 4 and 10. During all HDTBR time points, sleep, core temperature, and overnight transcutaneous CO2 were not different than the pre-HDTBR measurements. However, independent of the HDTBR intervention, the odds ratios {mean [95% confidence interval (CI)]} for developing Frisén grade optic disc edema were statistically significant for each hour below the mean total sleep time (2.2 [1.1-4.4]) and stage 2 nonrapid eye movement (NREM) sleep (4.8 [1.3-18.6]), and above the mean for wake after sleep onset (3.6 [1.2-10.6]) and for each 0.1°C decrease in core temperature amplitude below the mean (4.0 [1.4-11.7]). These data suggest that optic disc edema occurring during HDTBR was more likely to occur in those with short sleep duration and/or blunted temperature amplitude.NEW & NOTEWORTHY We determined that sleep and 24-h core body temperature were unaltered by 30 days exposure to the spaceflight analog strict 6° head-down tilt bed rest (HDTBR) in a 0.5% CO2 environment. However, shorter sleep duration, greater wake after sleep onset, and lower core temperature amplitude present throughout the study were associated with the development of optic disc edema, a key finding of spaceflight-associated neuro-ocular syndrome.
NEW MATERIAL:A compound expressed by formula I (A is expressed by formulas II, III or IV; X is ethylene or cis-vinylene; the bonds between the carbon atoms at the 13-, 14- and 15-positions are expressed by formula V when A is expressed by formula IIor III, and formula VI when A is expressed by formula IV; R is 1-12C straight chain or branched chain alkyl; R<1> is single bond, 1-5C straight chain or branched chain alkylene; R<2> is 1-8C straight chain or branched chain alkyl; etc.; the double bond between the carbon atoms at the 9- and 10-positions in formulas III and IV is Z; the double bond between carbon atoms at the 13- and 14-positions in formula V is E; the double bond between carbon atoms the 12- and 13-positions and the double bond between carbon atoms at the 14- and 15-positions in formula VI are E, Z or a mixture thereof) or a cyclodextrin clathrate compound thereof. EXAMPLE:2-Decarboxy-2-methyl-PGD2. USE:An antitumor agent having almost no pharmacological action unique to prostaglandin. PREPARATION:Compounds expressed by formulas VII and VIII (R<3> is tetrahydropyran-2-yl, etc.) are hydrolyzed under acidic conditions to give the compound expressed by formula I (A is expressed by formula II or III).
In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
The present invention relates to an injectable formulation comprising progesterone, progestin or analogues thereof, wherein a portion of said hormone is dissolved in an organic solvent to form a free portion and a portion of said hormone is enclosed by fatty acids to form an enclosed portion and wherein both portions are included in a gel matrix. This formulation allows a controlled release profile of progesterone to promote ovulation or synchronizing the ovulation or heat/estrus of a group of female mammals more effectively than intra-vaginal devices commonly used in the art. In general, hormone formulations, dosage units including the hormone formulations, and methods of use relate to a controlled release formulation, which includes hormones, e.g., progesterone are described. Formulations and methods are for controlling the reproductive cycle and/or ovulation of a female mammal, for example, to promote ovulation in a female mammal or synchronizing the ovulation or heat/estrus of a group of female mammals. In addition, formulations are for increasing the likelihood that a female mammal becomes pregnant, for example, after insemination or embryo transference. In addition, formulations are for reducing the anestrous period in a female mammal.
PROBLEM TO BE SOLVED: To obtain the subject drug capable of preventing and treating skin tissue disturbance by including 3-methyl-1-phenyl-2-pyrazolin-5-one. SOLUTION: This drug contains 3-methyl-1-phenyl-2-pyrazolin-5 one or a salt thereof as an active ingredient. The drug can be prepared as an oral or a parenteral administration form when clinically applied. The divided dose of the compound for an adult is 1-100 mg, and the compound is administered one to three times a day in the case of an oral administration. The divided dose thereof is 0.01-50 mg and the compound is administered two to five times a day in the case of an intravenous injection. Further, the divided dose thereof is 1-100 mg, and the compound is administered one to three times a day in the case of an intrarectal administration. The drug can be also administered by coating or affixing the compound.  The drug is useful for medical treatment and a treatment for beauty because the drug can prevent and treat a skin tissue disturbance such as sunburn, pigmentation, skin cancer, senility and photohypersensitivity.
INTRODUCTION: Ureteroscopy (URS) and retrograde intrarenal surgery (RIRS) are minimally invasive urologic procedures that are commonly used to treat kidney stones. However, they often result in significant postoperative pain. Historically, patients undergoing these surgeries have predominantly been managed with opioids, which has contributed to the escalating global complications associated with these drugs, including abuse and addiction. As a result, over the recent years, many healthcare centers have made efforts to minimize opioid use, opting instead for safer alternative medications. In this study, we aim to compare the efficacy of both opioid and opioid-free pain management regimens following URS or RIRS procedures.
EVIDENCE ACQUISITION: A systematic search was conducted in MEDLINE, Embase, Scopus, Cochrane, LILACS, and Google Scholar. We included studies that compared opioid-based and opioid-free postoperative care for managing pain in patients who underwent URS or RIRS for lithotripsy. Our primary outcome of interest was the frequency of postoperative emergency department (ED) visits. Secondary outcomes included pain-related phone calls, postoperative unexpected encounters, need for opioids at discharge, and patients with opioid refills.
EVIDENCE SYNTHESIS: We retrieved 10 articles, encompassing 6786 patients in the opioid group and 5276 patients in the opioid-free group. Overall, our findings lean towards favoring the opioid-free regimen, revealing notable differences between the groups. Opioid-free regimen was associated with less ED visits (OR=0.67; 95% CI: 0.58, 0.77; P=0.00001; I2=0%) and required less opioids at discharge (OR=0.11; 95% CI 0.02, 0.64; P=0.01; I2=89%).
CONCLUSIONS: Through statistically superior results, our meta-analysis suggests that an opioid-free regimen outperforms the use of opioids after URS or RIRS, particularly in terms of pain management.
Heterotopic ossification (HO) comprises the abnormal formation of ectopic bone in extraskeletal soft tissue. The factors that initiate HO remain elusive. Herein, we found that calcified apoptotic vesicles (apoVs) led to increased calcification and stiffness of tendon extracellular matrix (ECM), which initiated M2 macrophage polarization and HO progression. Specifically, single-cell transcriptome analyses of different stages of HO revealed that calcified apoVs were primarily secreted by a PROCR+ fibroblast population. In addition, calcified apoVs enriched calcium by annexin channels, absorbed to collagen I via electrostatic interaction, and aggregated to produce calcifying nodules in the ECM, leading to tendon calcification and stiffening. More importantly, apoV-releasing inhibition or macrophage deletion both successfully reversed HO development. Thus, we are the first to identify calcified apoVs from PROCR+ fibroblasts as the initiating factor of HO, and might serve as the therapeutic target for inhibiting pathological calcification.
The participants in the experimental activity groups will perform an interval physical activity of different intensity for 16 minutes. The intensity will be controlled during the test by the monitorization of their heart rate using a heart rate monitor. Subsequently, participants will perform an active break in the classroom after finishing one of their usual theory sessions at the intensity of physical activity that proves to have the greatest benefits for cognition and well-being.
The invention relates to a technique for the transfer of natural passive immunity via the colostrum of gestating cows infected with SARS-COV-2. These COVID19 cows developed immunity, producing colostrum rich in anti-SARS-COV-2 IgG antibodies. This colostrum is a natural probiotic of the immunised cow having circulating anti-SARS-COV-2 antibodies which is curative and preventive for patients infected with COVID19 and healthy patients. The worsening of cases is found in patients with serious pathological conditions and patients who are overweight. SARS-COV-2 infection causes severe respiratory distress ending up in intensive care; feeding can be done using a feeding tube, the viral load is stopped by this probiotic, but the prognosis is poor from the pulmonary and cerebral point of view. COVID19 patients who have recovered develop anti-SARS-COV-2 antibody immunity that can be seen in the serological test. This colostrum is stored using a cold lyophilisation technique which makes it possible to keep the anti-SARS-COV-2 IgGs 99% viable.